Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 22377673)

1.

Proteasome inhibitors for cancer therapy.

Iqbal M, Messina McLaughlin PA, Dunn D, Mallya S, Husten J, Ator MA, Chatterjee S.

Bioorg Med Chem. 2012 Apr 1;20(7):2362-8. doi: 10.1016/j.bmc.2012.02.007. Epub 2012 Feb 11.

PMID:
22377673
2.

The persisting challenge of selective and specific proteasome inhibition.

Groll M, Huber R, Moroder L.

J Pept Sci. 2009 Feb;15(2):58-66. doi: 10.1002/psc.1107. Review.

PMID:
19109822
3.

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.

Dick LR, Fleming PE.

Drug Discov Today. 2010 Mar;15(5-6):243-9. doi: 10.1016/j.drudis.2010.01.008. Epub 2010 Jan 29. Review.

PMID:
20116451
4.

The potential of proteasome inhibitors in cancer therapy.

Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O.

Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879 . Review.

PMID:
18491989
5.

[Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].

Tahmatzopoulos A, Gudegast C, Stöckle M, Wullich B, Unteregger G, Zwergel U, Zwergel T.

Aktuelle Urol. 2004 Nov;35(6):491-6. Review. German.

PMID:
15526229
6.

Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.

Nakata W, Hayakawa Y, Nakagawa H, Sakamoto K, Kinoshita H, Takahashi R, Hirata Y, Maeda S, Koike K.

Int J Oncol. 2011 Dec;39(6):1529-36. doi: 10.3892/ijo.2011.1141. Epub 2011 Jul 22.

PMID:
21785822
7.

[Proteasome inhibitor].

Yamamura M, Hirai T, Yamaguchi Y.

Nihon Rinsho. 2010 Jun;68(6):1079-84. Review. Japanese.

PMID:
20535959
8.

Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.

Zhu Y, Yao S, Xu B, Ge Z, Cui J, Cheng T, Li R.

Bioorg Med Chem. 2009 Oct 1;17(19):6851-61. doi: 10.1016/j.bmc.2009.08.023. Epub 2009 Aug 20.

PMID:
19747832
9.

Proteasome inhibition: a new approach for the treatment of malignancies.

Spano JP, Bay JO, Blay JY, Rixe O.

Bull Cancer. 2005 Nov;92(11):E61-6, 945-52. Review. English, French.

PMID:
16316823
10.

Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.

Colland F.

IDrugs. 2006 Mar;9(3):179-81. No abstract available.

PMID:
16523381
11.

Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.

Yang H, Landis-Piwowar KR, Chen D, Milacic V, Dou QP.

Curr Protein Pept Sci. 2008 Jun;9(3):227-39. Review.

12.

Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.

Zhu Y, Zhu X, Wu G, Ma Y, Li Y, Zhao X, Yuan Y, Yang J, Yu S, Shao F, Li R, Ke Y, Lu A, Liu Z, Zhang L.

J Med Chem. 2010 Mar 11;53(5):1990-9. doi: 10.1021/jm901407s.

PMID:
20158184
13.

Drug discovery and assay development in the ubiquitin-proteasome system.

Berkers CR, Ovaa H.

Biochem Soc Trans. 2010 Feb;38(Pt 1):14-20. doi: 10.1042/BST0380014.

PMID:
20074028
14.

Targeting the proteasome pathway.

Tsukamoto S, Yokosawa H.

Expert Opin Ther Targets. 2009 May;13(5):605-21. doi: 10.1517/14728220902866851 . Review.

PMID:
19397479
15.

Novel organic proteasome inhibitors identified by virtual and in vitro screening.

Basse N, Montes M, Maréchal X, Qin L, Bouvier-Durand M, Genin E, Vidal J, Villoutreix BO, Reboud-Ravaux M.

J Med Chem. 2010 Jan 14;53(1):509-13. doi: 10.1021/jm9011092.

PMID:
19919035
16.

Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.

Tsukamoto S, Yokosawa H.

Planta Med. 2010 Aug;76(11):1064-74. doi: 10.1055/s-0029-1240901. Epub 2010 Feb 25. Review.

PMID:
20186654
17.

Proteasome: an emerging target for cancer therapy.

Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K, Sezer O.

Anticancer Drugs. 2005 Jun;16(5):475-81. Review.

PMID:
15846112
18.

Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.

Watanabe T, Momose I, Abe M, Abe H, Sawa R, Umezawa Y, Ikeda D, Takahashi Y, Akamatsu Y.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2343-5. doi: 10.1016/j.bmcl.2009.02.117. Epub 2009 Mar 4.

PMID:
19307118
19.

Macrocyclic proteasome inhibitors.

Krahn D, Ottmann C, Kaiser M.

Curr Med Chem. 2011;18(33):5052-60. Review.

PMID:
22050753
20.

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL.

Bioorg Med Chem Lett. 1998 Feb 17;8(4):333-8.

PMID:
9871680
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk